Monday, 4 June 2012

Xiaflex moves a step closer

Shares in Auxilium Pharmaceuticals rose today after the company confirmed that it intends to file for marketing approval of Xiaflex by the end of the year. This announcement comes after the treatment met the study goals in two Phase III studies and as such is now viewed to be a viable treatment for peyronie's disease. This is certainly a promising development for peyronie's disease sufferers worldwide. Note that this is not a 'cure', but has been demonstrated in studies to reduce curvature. Dr. Culley Carson, a professor of urology at the University of North Carolina stated that the results “are not overwhelming and dramatic”. Let's not forget though that in men cases men do not need overwhelming results, they need results that allow for normal sexual functioning.

It's worth noting that traction is used in the Xiaflex study to remodel the penis post injections. It is already known that traction can reduce penile curvature and as such, it would likely to useful to compare 'traction vs xiaflex + traction' studies at some point.

I'm told that Xiaflex injections will likely be available towards the end of 2013. This treatment has been covered on the Peyronie's Disease UK site previously, but for the sake of completeness I'll endeavour to put together a new post over the next few days covering injectable treatments such as Xiaflex and Verapamil injections.

No comments:

Post a Comment

Note: only a member of this blog may post a comment.